Fig. 5

CLDN6 expression is associated with shorter OS in EAC and GAC cohorts. A-C OS in patient cohorts of EAC dichotomized by presence of CLDN6-negative and CLDN6-positive tumors. Primary surgery cohort = patients without neoadjuvant treatment before surgery; Neoadjuvant treatment cohort = patients treated with CROSS and FLOT regime. D–F OS in patient cohorts of GAC dichotomized by CLDN6 expression (positive vs. negative); Neoadjuvant treatment cohort included patients treated with PFL, MAGIC and FLOT regimens; A p-value < 0.05 (log-rank test) was considered significant. CLDN6 claudin 6, CROSS Chemo-radiotherapy for Oesophageal cancer followed by Surgery Study, EAC esophageal adenocarcinoma, FLOT fluorouracil-leucovorin-oxaliplatin-docetaxel, GAC gastric adenocarcinoma, MAGIC Medical Research Council Adjuvant Gastric Infusional Chemotherapy, OS overall survival, PFL Cisplatin, 5-Fluorouracil and Leucovorin